Mast announces plans for development of Vepoloxamer in heart failure
Consistent with prior guidance, earlier this year, Mast Therapeutics submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA), together with the protocol
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.